In reply
- PMID: 25745055
- PMCID: PMC4350808
- DOI: 10.1634/theoncologist.2014-423
In reply
Abstract
The authors are currently conducting molecular and genetic research to identify new targets for therapeutic interventions and predictive biomarkers in pseudomyxoma peritonei. The final aim of these studies is to rationalize the choice of treatment, which remains an unmet clinical need.
Comment on
-
FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma.Oncologist. 2014 Aug;19(8):845-50. doi: 10.1634/theoncologist.2014-0106. Epub 2014 Jun 20. Oncologist. 2014. PMID: 24951608 Free PMC article.
-
Challenges of efficacy assessments in pseudomyxoma peritonea.Oncologist. 2015 Mar;20(3):e3-4. doi: 10.1634/theoncologist.2014-0415. Oncologist. 2015. PMID: 25745054 Free PMC article.
References
-
- Carr NJ, Sobin LH. Adenocarcinoma of the appendix. In: Bosman FT, Carneiro F, Hruban RH, et al., editors. WHO Classification of Tumors of the Digestive System. Vol. 3. Lyon, France: International Agency for Research on Cancer; 2010. pp. 93–102.
-
- Misdraji J, Yantiss RK, Graeme-Cook FM, et al. Appendiceal mucinous neoplasms: A clinicopathologic analysis of 107 cases. Am J Surg Pathol. 2003;27:1089–1103. - PubMed
-
- Carr NJ, Finch J, Ilesley IC, et al. Pathology and prognosis in pseudomyxoma peritonei: A review of 274 cases. J Clin Pathol. 2012;65:919–923. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical